MC 02331

Drug Profile

MC 02331

Latest Information Update: 04 Oct 2004

Price : $50

At a glance

  • Originator Essential Therapeutics [CEASED]
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 04 Oct 2004 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 26 Jul 2001 No-Development-Reported for Bacterial infections in USA (Unknown route)
  • 13 May 1997 An animal study has been added in the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top